Extended Adherence to Adjuvant Endocrine Therapy in Breast Cancer Survivors: Ritualization of Adherence

Elizabeth Croson
Background: Hormone-receptor positive breast cancer survivors traditionally were prescribed adjuvant endocrine therapy (AET) for five years at the completion of definitive therapies. The duration of treatment continues to be explored with recommendations indicating that eight to ten years may be more effective in the prevention of breast cancer recurrence. Non-adherence rates are as high as 50% disruption or discontinuation before the recommendation of the provider. With extended durations of treatment, non-adherence rates will continue to...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.